blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2470173

EP2470173 - COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.03.2017
Database last updated on 07.10.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Abraxis BioScience, LLC
11755 Wilshire Boulevard, Suite 2100
Los Angeles, CA 90025 / US
[2015/36]
Former [2012/27]For all designated states
Abraxis BioScience, LLC
11755 Wilshire Boulevard
Suite 2100
Los Angeles, CA 90025 / US
Inventor(s)01 / TAO, Chunlin
1800 Camden Avenue
Suite No.301
Los Angeles CA 90025 / US
02 / DESAI, Neil, P.
11755 Wilshire Boulevard
Suite 2100
Los Angeles CA 90025 / US
03 / SOON-SHIONG, Patrick
149 South Barrington Avenue No.311
Los Angeles CA 90049 / US
 [2012/27]
Representative(s)Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
[2016/17]
Former [2012/27]Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11
80538 München / DE
Application number, filing date10812593.125.08.2010
[2016/17]
WO2010US46684
Priority number, dateUS20090236813P25.08.2009         Original published format: US 236813 P
[2012/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011025838
Date:03.03.2011
Language:EN
[2011/09]
Type: A1 Application with search report 
No.:EP2470173
Date:04.07.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 03.03.2011 takes the place of the publication of the European patent application.
[2012/27]
Type: B1 Patent specification 
No.:EP2470173
Date:27.04.2016
Language:EN
[2016/17]
Search report(s)International search report - published on:US03.03.2011
(Supplementary) European search report - dispatched on:EP22.05.2013
ClassificationIPC:A61K31/337, A61K9/20
[2012/27]
CPC:
A61K9/5169 (EP,KR,US); A61K31/337 (EP,KR,US); A61K47/42 (KR,US);
A61K31/4355 (KR,US); A61K31/7056 (KR,US); A61K9/0053 (KR);
A61P35/00 (EP); A61P35/02 (EP); A61P43/00 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/27]
Extension statesBA21.03.2012
ME21.03.2012
RS21.03.2012
TitleGerman:KOMBINATIONSTHERAPIE MIT NANOPARTIKELZUSAMMENSETZUNGEN AUS TAXAN UND HEDGEHOG-HEMMERN[2012/27]
English:COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS[2012/27]
French:PLURITHÉRAPIE AVEC DES COMPOSITIONS NANOPARTICULAIRES DE TAXANE ET DES INHIBITEURS HEDGEHOG[2012/27]
Entry into regional phase21.03.2012National basic fee paid 
21.03.2012Search fee paid 
21.03.2012Designation fee(s) paid 
21.03.2012Examination fee paid 
Examination procedure21.03.2012Examination requested  [2012/27]
10.12.2013Amendment by applicant (claims and/or description)
28.04.2014Despatch of a communication from the examining division (Time limit: M04)
05.09.2014Reply to a communication from the examining division
02.02.2015Communication of intention to grant the patent
26.05.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
12.08.2015Communication of intention to grant the patent
11.12.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
11.12.2015Fee for grant paid
11.12.2015Fee for publishing/printing paid
09.03.2016Information about intention to grant a patent
09.03.2016Receipt of the translation of the claim(s)
Divisional application(s)EP16167017.9  / EP3103452
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.04.2014
Opposition(s)30.01.2017No opposition filed within time limit [2017/14]
Fees paidRenewal fee
27.08.2012Renewal fee patent year 03
27.08.2013Renewal fee patent year 04
27.08.2014Renewal fee patent year 05
27.08.2015Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL27.04.2016
BG27.04.2016
CY27.04.2016
EE27.04.2016
IS27.04.2016
LT27.04.2016
LV27.04.2016
MC27.04.2016
MK27.04.2016
RO27.04.2016
SI27.04.2016
SM27.04.2016
GR28.07.2016
MT31.08.2016
[2018/46]
Former [2018/38]BG27.04.2016
CY27.04.2016
EE27.04.2016
IS27.04.2016
LT27.04.2016
LV27.04.2016
MC27.04.2016
MK27.04.2016
RO27.04.2016
SI27.04.2016
SM27.04.2016
GR28.07.2016
MT31.08.2016
Former [2018/33]CY27.04.2016
EE27.04.2016
IS27.04.2016
LT27.04.2016
LV27.04.2016
MC27.04.2016
MK27.04.2016
RO27.04.2016
SI27.04.2016
SM27.04.2016
GR28.07.2016
MT31.08.2016
Former [2018/30]CY27.04.2016
EE27.04.2016
IS27.04.2016
LT27.04.2016
LV27.04.2016
MC27.04.2016
MK27.04.2016
RO27.04.2016
SI27.04.2016
SM27.04.2016
GR28.07.2016
Former [2018/29]CY27.04.2016
EE27.04.2016
LT27.04.2016
LV27.04.2016
MC27.04.2016
MK27.04.2016
RO27.04.2016
SI27.04.2016
SM27.04.2016
GR28.07.2016
Former [2017/23]EE27.04.2016
LT27.04.2016
LV27.04.2016
MC27.04.2016
RO27.04.2016
SI27.04.2016
SM27.04.2016
GR28.07.2016
Former [2017/13]EE27.04.2016
LT27.04.2016
LV27.04.2016
RO27.04.2016
SM27.04.2016
GR28.07.2016
Former [2017/10]EE27.04.2016
LT27.04.2016
LV27.04.2016
RO27.04.2016
GR28.07.2016
Former [2016/51]LT27.04.2016
LV27.04.2016
GR28.07.2016
Former [2016/46]LT27.04.2016
Documents cited:Search[I]WO2006039569  (UNIV CHICAGO [US], et al) [I] 1-15 * examples 8-13; claims 1, 9 *;
 [A]  - HAWKINS ET AL, "Protein Nanoparticles as drug carriers in clinical medicine.", ADVANCED DRUG DELIVERY, (20080207), vol. 60, pages 876 - 885, XP002696596 [A] 1-15 * paragraph [0006] *

DOI:   http://dx.doi.org/10.1016/j.addr.2007.08.044
 [A]  - LOBO ET AL, "Paclitaxel albumin bound particles in combination with bevacizumab with or without gemcitabine.", BIOMEDICINE AND PHARMACOTHERAPY., (20070912), vol. 61, pages 531 - 533, XP002696597 [A] 1-15 * paragraph [0004] *

DOI:   http://dx.doi.org/10.1016/J.BIOPHA.2007.08.008
International search[Y]US2007116761  (DESAI NEIL P [US], et al);
 [Y]US2007281040  (WEICHSELBAUM RALPH R [US], et al);
 [Y]US2009123932  (MES-MASSON ANNE-MARIE [CA], et al);
 [A]WO2009086324  (GENENTECH INC [US], et al)
Examination   - LI ET AL, ADV. DRUG. DELIV. REV, (20080522), vol. 60, no. 8, pages 886 - 898
    - LANGER ET AL, J.THORACIC ONCOL., (20080601), vol. 3, no. 6, pages 623 - 630
by applicantUS5916596
 US6096331
 US6506405
 US6537579
 US2003166543
 US2004038876
 US2004110663
 US6749868
 US2004127474
 US2005004002
 US2005085519
 US2005112125
 US2005222087
 US2006263434
 US2007082838
 US2008019961
 WO2008137148
 WO2009086416
 US2010037986
 US2010037717
    - RUBIN ET AL., NATURE REVIEWS DRUG DISCOVERY, (2006), vol. 5, pages 1026 - 1033
    - BRUNTON ET AL., J. MEDICINAL CHEMISTRY, (2008), vol. 51, no. 5, pages 1108 - 1110
    - ROMER ET AL., CANCER RESEARCH, (2005), vol. 65, pages 4975 - 4978
    - CHEN ET AL., PROC. NAT. ACAD. SCI., (2002), vol. 99, no. 22, pages 14071 - 14076
    - TAIPALE ET AL., NATURE, (2002), vol. 418, pages 892 - 897
    - TAIPALE ET AL., NATURE, (2000), vol. 406, pages 1005 - 1009
    - TULLIS, JAMA, (1977), vol. 237, pages 355 - 360,460-463
    - HOUSER ET AL., SURGERY, GYNECOLOGY AND OBSTETRICS, (1980), vol. 150, pages 811 - 816
    - FINLAYSON, SEMINARS IN THROMBOSIS AND HEMOSTASIS, (1980), vol. 6, pages 85 - 120
    - FEHSKE ET AL., BIOCHEM. PHARMCOL., vol. 30, pages 687 - 92
    - VORUM, DAN. MED. BULL., (1999), vol. 46, pages 379 - 99
    - KRAGH-HANSEN, DAN. MED. BULL., (1990), vol. 1441, pages 131 - 40
    - CURRY ET AL., NAT. STRUCT. BIOL., (1998), vol. 5, pages 827 - 35
    - SUGIO ET AL., PROTEIN. ENG., (1999), vol. 12, pages 439 - 46
    - HE ET AL., NATURE, vol. 358, pages 209 - 15
    - CARTER ET AL., ADV. PROTEIN. CHEM., (1994), vol. 45, pages 153 - 203
    - PAAL ET AL., EUR. J. BIOCHEM., vol. 268, no. 7, pages 2187 - 91
    - PURCELL ET AL., BIOCHIM. BIOPHYS. ACTA, (2000), vol. 1478, pages 61 - 8
    - ALTMAYER ET AL., ARZNEIMITTELFORSCHUNG, (1995), vol. 45, pages 1053 - 6
    - GARRIDO ET AL., REV. ESP. ANESTESTIOL. REANIM., (1994), vol. 41, pages 308 - 12
    - URIEN ET AL., INVEST. NEW DRUGS, (1996), vol. 14, pages 147 - 51
    - S. R. HINGORANI ET AL., CANCER CELL, (2005), vol. 7, page 469
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.